Welcome
Support Centre
07 August 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A multicentre, randomised controlled trial of cognitive therapy to reduce harmful compliance with command hallucinations
ISRCTN ISRCTN62304114
ClinicalTrials.gov identifier
Public title A multicentre, randomised controlled trial of cognitive therapy to reduce harmful compliance with command hallucinations
Scientific title
Acronym COMMAND
Serial number at source MRC ref: G0500965
Study hypothesis Main hypothesis: The group receiving the cognitive therapy (CTCH group) will show a lower level of compliance and appeasement behaviour and an increase in resistance compared with the control group

Secondary hypotheses: The CTCH group will show lower levels of conviction in the power of the voice and reduction in distress and depression compared to the control group

Publication from pilot study: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15056575
Ethics approval The trial was approved by the West Midlands Multi-centre Research Ethics Committee on the 5th of January 2007 (ref: 06/MRE07/71)
Study design Multi-centre, single-blind, randomised controlled trial with intention to treat.
Countries of recruitment United Kingdom
Disease/condition/study domain Command hallucinations
Participants - inclusion criteria 1. Aged 16-65
2. Primary diagnosis of International Statistical Classification of Diseases and Related Health Problems (ICD-10) schizophrenia or related disorder
3. History of experiencing command hallucinations (minimum 6 months) with risk of harm to self or others
Participants - exclusion criteria 1. Over 65 years of age
2. Primary diagnosis of organic brain disorder
3. Primary diagnosis of addictive substance misuse
4. Insufficient command of the English language
Anticipated start date 17/09/2007
Anticipated end date 31/01/2011
Status of trial Ongoing
Patient information material
Target number of participants 180 (60 participants from each of the three site)
Interventions Three UK sites will be taking part: Birmingham, London and Manchester.

Participants will be randomly allocated to two groups:
1. Cognitive Therapy for Command Hallucinations + Treatment As Usual (CTCH + TAU)
2. TAU only

The CTCH + TAU group will receive an average of 15 sessions (maximum 25 sessions in all) of cognitive therapy delivered by qualified clinical psychologists who will be regularly supervised by consultant psychologists. This cognitive therapy uses Cognitive Behavioural Therapy (CBT) to assess and modify conviction in four beliefs linked to the construct of voice power: i) that the voice has absolute power and control; ii) that the client must comply or appease or be severely punished; iii) the identity of the voice (e.g. the Devil) and iv) the meaning attached to the voice experience (e.g., the client is being punished for past bad behaviour).
Primary outcome measure(s) Compliance behaviour, assessed using the Cognitive Assessment of Voices Interview Schedule combined with the Revised Voice Compliance Scale. This is an observer rated scale to measure the level of compliance/resistance with each command, using information from the participant and at least one of three other informants (parent, spouse, keyworker). Each behaviour is then classified as:
1. Neither appeasement nor compliant
2. Symbolic appeasement, i.e. compliant with innocuous and/or harmless commands
3. Actual appeasement i.e. preparatory acts or gestures
4. Partial compliance with at least one severe command
5. Full compliance with at least one severe command

The ratings are taken at baseline, 9 and 18 months.
Secondary outcome measure(s) Beliefs about voices, distress and symptoms assessed at baseline, 9 and 18 months follow-up as follows:
1. Voice power is measured using the Voice Power Differential Scale (VPD) which measures the power differential between voice and voice hearer
2. Distress associated with delusions about voices is measured using the Psychotic Symptoms Rating Scales (PSYRATS)
3. Psychosis symptoms are rated using the Positive and Negative Symptom Scale (PANSS)
4. Beck Hopelessness scale & Beck Scale for Suicidal Ideation
5. Calgary Depression Scale
6. Personal Knowledge Questionnaire
7. Beliefs about voice questionnaire
8. Suicide and self-injury scale (SASII)
9. Childhood trauma questionnaire
Sources of funding Medical Research Council (UK)
Trial website
Publications
Contact name Prof  Max  Birchwood
  Address School of Psychology
University of Birmingham
Early Intervention Service
1 Miller Street
Aston
  City/town Birmingham
  Zip/Postcode B6 4NF
  Country United Kingdom
  Tel +44 (0)121 301 1850
  Fax +44 (0)121 301 1851
  Email birchmjz@bham.ac.uk
Sponsor University of Birmingham (UK)
  Address Research & Commercial Services
Aitchison Building
University of Birmingham
Edgbaston
  City/town Birmingham
  Zip/Postcode B15 2TT
  Country United Kingdom
  Tel +44 (0)121 414 7618
  Email b.w.laverty@bham.ac.uk
  Sponsor website: http://www.bham.ac.uk
Date applied 04/12/2007
Last edited 28/04/2008
Date ISRCTN assigned 27/03/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central